Converge Bio has raised $5.5 million in seed funding led by TLV Partners.
WHAT IT DOES
Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs that use large language models (LLMs).
The platform supplies a library of foundational models across all biological languages that can be amplified and adjusted for specific tasks with...
Google Research and Google DeepMind recently released a paper announcing the creation of a new LLM for drug discovery and therapeutic development dubbed Tx-LLM, fine-tuned from PaLM-2.
Tx-LLM utilizes the tech giant's PaLM-2, its generative AI technology that uses Google's LLMs to answer medical questions.
The drug discovery-focused LLM was trained using 709 datasets to target 66 tasks across...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup, TenAces.
TenAces will utilize AI, integrating biology and machine learning algorithms, to discover molecular glue therapies to enhance targeted protein degradation.
Molecular glues are protein-binding small molecules that change two protein...
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help of genAI technology.
The project will leverage Absci's Integrated Drug Creation platform – which combines scalable wet lab technologies with AI, and facilitates...
Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures.
CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also participated in the round.
WHAT IT DOES
Vivodyne is a drug discovery company that uses clinically predictive AI to help identify therapeutic targets and predict a patient's response to a drug by...
This week Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies like AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services, announced the formation of a new startup company dubbed OMEC.AI.
OMEC.AI aims to build a computational platform using AI that can help researchers assess the clinical trial readiness of a drug...
NuraLogix introduces health measurement app in Singapore
Canadian health AI company NuraLogix has introduced its mobile health measurement app in Singapore.
Anura uses proprietary transdermal optical imaging technology, which captures blood information from a person's face through a video camera. It can measure various vital parameters, including blood pressure, heart rate, stress level, cardiac...
Tohoku University's Tohoku Medical Megabank Organization, pharmaceutical firms Daiichi Sankyo and Takeda Pharmaceutical Co., and medical IT company MICIN have started a collaborative research project to track long-term lifestyle habits to drive the creation of new drugs.
According to a press statement, the organisations will loan wearable tracking devices to about 2,000 participants. Over a year...
ICT provider Fujitsu has partnered with research institute Riken in Japan to jointly work on new-generation IT drug discovery technology to accelerate digital transformation in drug discovery.
According to a press statement, the organisations will utilise the supercomputer Fugaku, which they have developed together in the past decade, along with simulation AI technologies. Through these...
AI-enabled pathology company PathAI has entered into a multiyear drug discovery partnership with pharma giant GlaxoSmithKline.
The agreement will focus on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease that can lead to serious scarring and liver failure.
"Our partnership will combine GSK and PathAI...
